Similar articles for PMID: 31806768

Year	Number of Results
2007	1
2009	2
2010	9
2011	6
2012	8
2013	10
2014	16
2015	11
2016	14
2017	17
2018	14
2019	18
2020	38
2021	42
2022	28
2023	16
2024	0

1

Comparison Between ¹⁸F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.

Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, Grossi F. Rossi G, et al. J Nucl Med. 2020 Jul;61(7):990-998. doi: 10.2967/jnumed.119.233056. Epub 2019 Dec 5. J Nucl Med. 2020. PMID: 31806768 Free article.

2

The utility of ⁶⁸F-FDG PET/CT for evaluation of tumor response to immune checkpoint inhibitor therapy and prognosis prediction in patients with non-small-cell lung cancer.

Kitajima K, Kawanaka Y, Komoto H, Minami T, Yokoi T, Kuribayashi K, Kijima T, Nakamura A, Hashimoto M, Kondo N, Hasegawa S, Yamakado K. Kitajima K, et al. Hell J Nucl Med. 2021 Sep-Dec;24(3):186-198. doi: 10.1967/s002449912402. Epub 2021 Dec 17. Hell J Nucl Med. 2021. PMID: 34901959 Free article.

3

Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC).

Fledelius J, Khalil AA, Hjorthaug K, Frøkiaer J. Fledelius J, et al. J Med Imaging Radiat Oncol. 2016 Apr;60(2):231-8. doi: 10.1111/1754-9485.12427. Epub 2015 Dec 18. J Med Imaging Radiat Oncol. 2016. PMID: 26678718

4

Comparison of RECIST, EORTC criteria and PERCIST for evaluation of early response to chemotherapy in patients with non-small-cell lung cancer.

Shang J, Ling X, Zhang L, Tang Y, Xiao Z, Cheng Y, Guo B, Gong J, Huang L, Xu H. Shang J, et al. Eur J Nucl Med Mol Imaging. 2016 Oct;43(11):1945-53. doi: 10.1007/s00259-016-3420-7. Epub 2016 May 28. Eur J Nucl Med Mol Imaging. 2016. PMID: 27236466 Clinical Trial.

5

Tumor response evaluation in patients with malignant melanoma undergoing immune checkpoint inhibitor therapy and prognosis prediction using ¹⁸F-FDG PET/CT: multicenter study for comparison of EORTC, PERCIST, and imPERCIST.

Kitajima K, Watabe T, Nakajo M, Ishibashi M, Daisaki H, Soeda F, Tanemura A, Kanekura T, Yamazaki N, Ito K. Kitajima K, et al. Jpn J Radiol. 2022 Jan;40(1):75-85. doi: 10.1007/s11604-021-01174-w. Epub 2021 Jul 21. Jpn J Radiol. 2022. PMID: 34287739 Free PMC article.

6

What ¹⁸F-FDG PET Response-Assessment Method Best Predicts Survival After Curative-Intent Chemoradiation in Non-Small Cell Lung Cancer: EORTC, PERCIST, Peter Mac Criteria, or Deauville Criteria?

Turgeon GA, Iravani A, Akhurst T, Beaulieu A, Callahan JW, Bressel M, Cole AJ, Everitt SJ, Siva S, Hicks RJ, Ball DL, Mac Manus MP. Turgeon GA, et al. J Nucl Med. 2019 Mar;60(3):328-334. doi: 10.2967/jnumed.118.214148. Epub 2018 Jul 20. J Nucl Med. 2019. PMID: 30030343 Free article. Clinical Trial.

7

The predictive value of ¹⁸F-FDG PET-CT for assessing the clinical outcomes in locally advanced NSCLC patients after a new induction treatment: low-dose fractionated radiotherapy with concurrent chemotherapy.

Mattoli MV, Massaccesi M, Castelluccia A, Scolozzi V, Mantini G, Calcagni ML. Mattoli MV, et al. Radiat Oncol. 2017 Jan 5;12(1):4. doi: 10.1186/s13014-016-0737-0. Radiat Oncol. 2017. PMID: 28057034 Free PMC article.

8

Comparison of Metabolic and Morphological Response Criteria for Early Prediction of Response and Survival in NSCLC Patients Treated With Anti-PD-1/PD-L1.

Castello A, Rossi S, Toschi L, Lopci E. Castello A, et al. Front Oncol. 2020 Jul 31;10:1090. doi: 10.3389/fonc.2020.01090. eCollection 2020. Front Oncol. 2020. PMID: 32850315 Free PMC article.

9

Comparison of RECIST, iRECIST, and PERCIST for the Evaluation of Response to PD-1/PD-L1 Blockade Therapy in Patients With Non-Small Cell Lung Cancer.

Beer L, Hochmair M, Haug AR, Schwabel B, Kifjak D, Wadsak W, Fuereder T, Fabikan H, Fazekas A, Schwab S, Mayerhoefer ME, Herold C, Prosch H. Beer L, et al. Clin Nucl Med. 2019 Jul;44(7):535-543. doi: 10.1097/RLU.0000000000002603. Clin Nucl Med. 2019. PMID: 31021918

10

¹⁸FDG PET/CT in the early assessment of non-small cell lung cancer response to immunotherapy: frequency and clinical significance of atypical evolutive patterns.

Humbert O, Cadour N, Paquet M, Schiappa R, Poudenx M, Chardin D, Borchiellini D, Benisvy D, Ouvrier MJ, Zwarthoed C, Schiazza A, Ilie M, Ghalloussi H, Koulibaly PM, Darcourt J, Otto J. Humbert O, et al. Eur J Nucl Med Mol Imaging. 2020 May;47(5):1158-1167. doi: 10.1007/s00259-019-04573-4. Epub 2019 Nov 23. Eur J Nucl Med Mol Imaging. 2020. PMID: 31760467

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

208 results

Results by year